Epigenetics of human cutaneous melanoma: Setting the stage for new therapeutic strategies

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Sigalotti, Luca ^a   Covre, Alessia ^a,b   Fratta, Elisabetta ^a   Parisi, Giulia ^a,b   Colizzi, Francesca ^a   Rizzo, Aurora ^a   Danielli, Riccardo ^b   Nicolay, Hugues J M ^b   Coral, Sandra ^a   Maio, Michele ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AZACITIDINE; BAY 865274; BELINOSTAT; CISPLATIN; DACARBAZINE; DEPAKOTE ER; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; ENTINOSTAT; EPIGALLOCATECHIN GALLATE; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; KARENITECIN; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N PHTHALOYLTRYPTOPHAN; PANOBINOSTAT; PDX 110; PEGINTERFERON ALPHA2B; PROCAINAMIDE; PROCAINE; RECOMBINANT ALPHA2B INTERFERON; ROMIDEPSIN; S 110; SNDX 275; STAVZOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ENZYME INHIBITOR; HISTONE; MICRORNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CLINICAL TRIAL; COLORECTAL CANCER; DNA MODIFICATION; DNA REPAIR; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; EPIGENETICS; ESOPHAGUS CANCER; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC MARKER; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MYELODYSPLASTIC SYNDROME; OVARY CANCER; PATENT; PLEURA MESOTHELIOMA; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CANCER; ARTICLE; DNA METHYLATION; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROTEIN PROCESSING; SKIN TUMOR;

DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONES; HUMANS; MELANOMA; MICRORNAS; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SKIN NEOPLASMS;

EID: 77953306334     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-56     Document Type: Review

References (161)

1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007, 82:364-380. 10.4065/82.3.364, 17352373.
2. Houghton AN, Polsky D. Focus on melanoma. Cancer Cell 2002, 2:275-278. 10.1016/S1535-6108(02)00161-7, 12398891.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
4. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006, 81:500-507. 10.4065/81.4.500, 16610570.
5. Schwabe M, Lubbert M. Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol 2007, 8:382-387. 10.2174/138920107783018372, 18289047.
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692. 10.1016/j.cell.2007.01.029, 17320506.
7. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009, 41:87-95. 10.1016/j.biocel.2008.09.005, 18834952.
8. Pradhan S, Bacolla A, Wells RD, Roberts RJ. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999, 274:33002-33010. 10.1074/jbc.274.46.33002, 10551868.
9. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998, 19:219-220. 10.1038/890, 9662389.
10. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257. 10.1016/S0092-8674(00)81656-6, 10555141.
11. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000, 404:1003-1007. 10.1038/35010000, 10801130.
12. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556. 10.1038/416552a, 11932749.
13. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 2002, 21:4183-4195. 10.1093/emboj/cdf401, 126147, 12145218.
14. Paz MF, Wei S, Cigudosa JC, Rodriguez-Perales S, Peinado MA, Huang TH, Esteller M. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003, 12:2209-2219. 10.1093/hmg/ddg226, 12915469.
15. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97. 10.1016/j.tibs.2005.12.008, 16403636.
16. Strathdee G, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med 2002, 4:1-17. 10.1017/S1462399402004222, 14987388.
17. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005, 19:563-573. 10.1210/me.2004-0496, 15677708.
18. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007, 14:1025-1040. 10.1038/nsmb1338, 17984965.
19. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chromatin structure during development. Nat Genet 2003, 34:187-192. 10.1038/ng1158, 12740577.
20. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50. 10.1038/nrd1930, 16485345.
21. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006, 66:11187-11193. 10.1158/0008-5472.CAN-06-1274, 17145863.
22. Bonazzi VF, Irwin D, Hayward NK. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes Cancer 2009, 48:10-21. 10.1002/gcc.20615, 18803327.
23. Hoek KS. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 2007, 20:466-484. 10.1111/j.1600-0749.2007.00412.x, 17935490.
24. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res 1980, 8:4777-4790. 10.1093/nar/8.20.4777, 324387, 7443525.
25. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992, 89:1827-1831. 10.1073/pnas.89.5.1827, 48546, 1542678.
26. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35:146-150.
27. Brena RM, Auer H, Kornacker K, Hackanson B, Raval A, Byrd JC, Plass C. Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic Acids Res 2006, 34:e17. 10.1093/nar/gnj017, 1361623, 16464820.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
29. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28:E32. 10.1093/nar/28.8.e32, 102836, 10734209.
30. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32:e38. 10.1093/nar/gnh032, 373427, 14973332.
31. Stach D, Schmitz OJ, Stilgenbauer S, Benner A, Dohner H, Wiessler M, Lyko F. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003, 31:E2. 10.1093/nar/gng002, 140527, 12527791.
32. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 2009, 19:1462-1470. 10.1101/gr.091447.109, 2720187, 19491193.
33. Ansorge WJ. Next-generation DNA sequencing techniques. N Biotechnol 2009, 25:195-203. 10.1016/j.nbt.2008.12.009, 19429539.
34. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298. 10.1038/nrg2005, 17339880.
35. Dasgupta P, Chellappan SP. Chromatin immunoprecipitation assays: molecular analysis of chromatin modification and gene regulation. Methods Mol Biol 2007, 383:135-152. full_text, 18217683.
36. Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997, 57:5336-5347.
37. Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, Randerson-Moor JA, Houghton A, Busam K, Timothy BD, Bastian BC, Newton-Bishop JA, Polsky D. Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 2008, 100:784-795. 10.1093/jnci/djn157, 18505964.
38. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Transl Med 2009, 7:86. 10.1186/1479-5876-7-86, 2770476, 19828018.
39. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004, 23:4014-4022. 10.1038/sj.onc.1207505, 2856469, 15064737.
40. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003, 63:1639-1643.
41. Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 2006, 66:2785-2793. 10.1158/0008-5472.CAN-05-2303, 1769551, 16510600.
42. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009, 15:1801-1807. 10.1158/1078-0432.CCR-08-1361, 2703821, 19223509.
43. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
44. Tellez CS, Shen L, Estecio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res 2009, 19:146-155. 10.1097/CMR.0b013e32832b274e, 19441164.
45. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996, 93:7149-7153. 10.1073/pnas.93.14.7149, 38951, 8692960.
46. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999, 19:7327-7335. 84726, 10523621.
47. Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother (1997) 2002, 25:16-26.
48. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021. 10.1111/j.1349-7006.2009.01303.x, 19719775.
49. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 2004, 64:9167-9171. 10.1158/0008-5472.CAN-04-1442, 15604288.
50. Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, Fonsatti E, Altomonte M, Calabro L, Coral S, Maio M. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 2010, 223:352-358.
51. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol 2008, 215:287-291. 10.1002/jcp.21380, 18205182.
52. Sigalotti L, Covre A, Nicolay HJ, Coral S, Maio M. Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. Cancer Immunol Immunother 2010, 59:487-488. 10.1007/s00262-009-0785-5, 19862522.
53. Florenes VA, Skrede M, Jorgensen K, Nesland JM. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res 2004, 14:173-181. 10.1097/01.cmr.0000129576.49313.26, 15179185.
54. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004, 3:425-435.
55. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211. 10.1038/35051606, 11196646.
56. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 2004, 64:7706-7710. 10.1158/0008-5472.CAN-03-3897, 15520174.
57. Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008, 21:525-533. 10.1111/j.1755-148X.2008.00495.x, 18761658.
58. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol 2007, 34:597-600. 10.1111/j.1600-0560.2006.00678.x, 17640228.
59. Richards HW, Medrano EE. Epigenetic marks in melanoma. Pigment Cell Melanoma Res 2009, 22:14-29. 10.1111/j.1755-148X.2008.00534.x, 19040501.
60. Roesch A, Becker B, Schneider-Brachert W, Hagen I, Landthaler M, Vogt T. Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. J Invest Dermatol 2006, 126:1850-1859. 10.1038/sj.jid.5700324, 16645588.
61. Mueller DW, Bosserhoff AK. Role of miRNAs in the progression of malignant melanoma. Br J Cancer 2009, 101:551-556. 10.1038/sj.bjc.6605204, 19638982.
62. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009, 129:1740-1751. 10.1038/jid.2008.452, 19212343.
63. Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di LG, Ferracin M, Volinia S, Bonmassar E, Croce CM, D'Atri S. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol 2009, 35:393-400.
64. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008, 68:1362-1368. 10.1158/0008-5472.CAN-07-2912, 18316599.
65. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, varez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009, 106:1814-1819. 10.1073/pnas.0808263106, 2634798, 19188590.
66. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM, Giordano S. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008, 68:10128-10136. 10.1158/0008-5472.CAN-08-2148, 19074879.
67. Muller DW, Bosserhoff AK. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008, 27:6698-6706. 10.1038/onc.2008.282, 18679415.
68. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008, 18:549-557. 10.1038/cr.2008.45, 18379589.
69. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Care A. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008, 68:2745-2754. 10.1158/0008-5472.CAN-07-2538, 18417445.
70. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
71. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005, 97:1498-1506. 10.1093/jnci/dji311, 16234563.
72. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007, 67:6400-6408. 10.1158/0008-5472.CAN-07-0251, 17616700.
73. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984, 81:6993-6997. 10.1073/pnas.81.22.6993, 392062, 6209710.
74. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, Leonhardt H. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2005, 2:751-756. 10.1038/nmeth794, 16179921.
75. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood 2003, 101:4644-4646. 10.1182/blood-2002-11-3458, 12756166.
76. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006, 12:5777-5785. 10.1158/1078-0432.CCR-06-0669, 17020984.
77. Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van LE, Cullen M, MacLeod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 2008, 14:2444-2449. 10.1158/1078-0432.CCR-07-1320, 18413836.
78. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006, 24:159-167. 10.1007/s10637-006-5938-1, 16502349.
79. Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003, 21:85-97. 10.1023/A:1022976528441, 12795533.
80. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784. 10.1038/nrd2133, 16955068.
81. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabro L, Maio M. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007, 212:330-344. 10.1002/jcp.21066, 17458893.
82. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468. 10.1200/JCO.2009.22.1291, 19826124.
83. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 2009, 45:1129-1136. 10.1016/j.ejca.2009.01.003, 19211243.
84. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20:705-710. 10.1097/CCO.0b013e328313699c, 18841054.
85. Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 2006, 207:58-66. 10.1002/jcp.20540, 16252259.
86. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother (1997) 2001, 24:151-161.
87. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006, 66:1105-1113. 10.1158/0008-5472.CAN-05-3020, 2242843, 16424047.
88. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005, 19:103-111.
89. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, Kluger Y, Deng M, Tran N, Zhang W, Picardo M, Enghild JJ. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009, 4:e4563. 10.1371/journal.pone.0004563, 2642998, 19234609.
90. Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother 1999, 22:16-24. 10.1097/00002371-199901000-00003, 9924695.
91. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, Van Muijen GN, van Kessel AG. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 2000, 60:1654-1662.
92. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994, 54:1766-1771.
93. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 2006, 25:2873-2884. 10.1038/sj.onc.1209319, 16407841.
94. Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 2005, 65:2009-2017. 10.1158/0008-5472.CAN-04-3216, 15753401.
95. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer 2003, 105:430-431. 10.1002/ijc.11077, 12704681.
96. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007, 13:3333-3338. 10.1158/1078-0432.CCR-06-3091, 17545540.
97. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer 2001, 94:243-251. 10.1002/ijc.1452, 11668505.
98. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 2008, 27:490-498. 10.1038/sj.onc.1210655, 17653094.
99. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006, 24:3771-3779. 10.1200/JCO.2005.03.4074, 16801630.
100. Fulda S, Kufer MU, Meyer E, van VF, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877. 10.1038/sj.onc.1204750, 11593392.
101. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008, 21:545-558. 10.1111/j.1755-148X.2008.00484.x, 18627528.
102. Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 2004, 53:748-754. 10.1007/s00262-004-0513-0, 14997346.
103. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008, 57:647-654. 10.1007/s00262-007-0402-4, 18046553.
104. Khan AN, Magner WJ, Tomasi TB. An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med 2007, 5:64. 10.1186/1479-5876-5-64, 2231344, 18070359.
105. Murakami T, Sato A, Chun NA, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki M, Furukawa Y, Kobayashi E. Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma. J Invest Dermatol 2008, 128:1506-1516. 10.1038/sj.jid.5701216, 18185535.
106. Gillespie S, Borrow J, Zhang XD, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006, 11:2251-2265. 10.1007/s10495-006-0283-6, 17051334.
107. Kozar K, Kaminski R, Switaj T, Oldak T, Machaj E, Wysocki PJ, Mackiewicz A, Lasek W, Jakobisiak M, Golab J. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 2003, 9:3124-3133.
108. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la RP, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009, 69:8693-8699. 10.1158/0008-5472.CAN-09-1456, 19861533.
109. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006, 12:4619-4627. 10.1158/1078-0432.CCR-06-0883, 16899610.
110. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007, 6:70-81. 10.1158/1535-7163.MCT-06-0125, 17237267.
111. Hellebrekers DM, Jair KW, Vire E, Eguchi S, Hoebers NT, Fraga MF, Esteller M, Fuks F, Baylin SB, van EM, Griffioen AW. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006, 5:467-475. 10.1158/1535-7163.MCT-05-0417, 16505122.
112. Alvino E, Castiglia D, Caporali S, Pepponi R, Caporaso P, Lacal PM, Marra G, Fischer F, Zambruno G, Bonmassar E, Jiricny J, D'Atri S. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 2006, 29:785-797.
113. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001, 92:123-129. 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.0.CO;2-V, 11279615.
114. Valentini A, Gravina P, Federici G, Bernardini S. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther 2007, 6:185-191. 10.4161/cbt.6.2.3578, 17218782.
115. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009, 15:2479-2487. 10.1158/1078-0432.CCR-08-1931, 19318485.
116. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009, 101:1044-1050. 10.1038/sj.bjc.6605293, 19738609.
117. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nole F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009, 100:28-36. 10.1038/sj.bjc.6604817, 2634690, 19127265.
118. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008, 18:274-278. 10.1097/CMR.0b013e328307c248, 18626312.
119. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005, 11:4912-4922. 10.1158/1078-0432.CCR-04-2088, 16000590.
120. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006, 5:1967-1974. 10.1158/1535-7163.MCT-06-0022, 16928817.
121. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH. Methylation of PTEN as a Prognostic Factor in Malignant Melanoma of the Skin. J Invest Dermatol 2009, 130:620-622. 10.1038/jid.2009.226, 19798057.
122. Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2009, 126:2553-2562.
123. Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ, Hoon DS. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 2006, 66:6692-6698. 10.1158/0008-5472.CAN-06-0801, 2856460, 16818643.
124. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, Vu VD, Nguyen SL, Hoon DS. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005, 23:9351-9358. 10.1200/JCO.2005.02.9876, 2856438, 16361635.
125. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 2007, 67:11335-11343. 10.1158/0008-5472.CAN-07-1502, 18056460.
126. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008, 26:2299-2304. 10.1200/JCO.2007.14.5292, 18467721.
127. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M, Lyko F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005, 65:6305-6311. 10.1158/0008-5472.CAN-04-2957, 16024632.
128. Sharma BK, Smith CC, Laing JM, Rucker DA, Burnett JW, Aurelian L. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions. Dermatology 2006, 213:192-199. 10.1159/000095035, 17033167.
129. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004, 95:962-968. 10.1111/j.1349-7006.2004.tb03184.x, 15596045.
130. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006, 126:422-431. 10.1038/sj.jid.5700073, 16374457.
131. Guan X, Sagara J, Yokoyama T, Koganehira Y, Oguchi M, Saida T, Taniguchi S. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer 2003, 107:202-208. 10.1002/ijc.11376, 12949795.
132. Worm J, Bartkova J, Kirkin AF, Straten P, Zeuthen J, Bartek J, Guldberg P. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 2000, 19:5111-5115. 10.1038/sj.onc.1203891, 11042700.
133. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 C > T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002, 161:229-237. 1850679, 12107107.
134. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ, Culhane AC, McArdle L, Fraga MF, Hughes L, Currid CA, O'Mahony F, Byrne A, Murphy AA, Moss C, McDonnell S, Stallings RL, Plumb JA, Esteller M, Brown R, Dervan PA, Easty DJ. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 2005, 26:1856-1867. 10.1093/carcin/bgi152, 15958521.
135. Takeuchi T, Adachi Y, Sonobe H, Furihata M, Ohtsuki Y. A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion. Oncogene 2006, 25:7059-7069. 10.1038/sj.onc.1209688, 16715130.
136. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 2004, 23:5215-5226. 10.1038/sj.onc.1207647, 15133491.
137. Lin YC, You L, Xu Z, He B, Yang CT, Chen JK, Mikami I, Clement G, Shi Y, Kuchenbecker K, Okamoto J, Kashani-Sabet M, Jablons DM. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 2007, 18:379-386. 10.1089/hum.2006.005, 17472570.
138. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006, 66:6080-6086. 10.1158/0008-5472.CAN-06-0157, 16778180.
139. Kohonen-Corish MR, Cooper WA, Saab J, Thompson JF, Trent RJ, Millward MJ. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 2006, 126:167-171. 10.1038/sj.jid.5700005, 16417233.
140. Grunau C, Sanchez C, Ehrlich M, van der BP, Hindermann W, Rodriguez C, Krieger S, Dubeau L, Fiala E, De SA. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 2005, 43:11-24. 10.1002/gcc.20155, 15704127.
141. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, Koyanagi K, Hoon DS. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005, 65:1800-1807. 10.1158/0008-5472.CAN-04-3531, 15753377.
142. McGuinness C, Wesley UV. Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation. Front Biosci 2008, 13:2435-2443. 10.2741/2856, 17981724.
143. Denk AE, Bettstetter M, Wild PJ, Hoek K, Bataille F, Dietmaier W, Bosserhoff AK. Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res 2007, 20:112-119. 10.1111/j.1600-0749.2007.00363.x, 17371437.
144. Wada K, Maesawa C, Akasaka T, Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol 2004, 122:805-811. 10.1111/j.0022-202X.2004.22308.x, 15086568.
145. Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H, Ushijima T. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007, 121:301-307. 10.1002/ijc.22637, 17372906.
146. Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, Ushijima T. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res 2005, 15:15-20. 10.1097/00008390-200502000-00004, 15714116.
147. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006, 66:6546-6552. 10.1158/0008-5472.CAN-06-0384, 16818626.
148. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, Akasaka T, Masuda T. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol 2007, 30:689-694.
149. Cheng E, Trombetta SE, Kovacs D, Beech RD, Ariyan S, Reyes-Mugica M, McNiff JM, Narayan D, Kluger HM, Picardo M, Halaban R. Rab33A: characterization, expression, and suppression by epigenetic modification. J Invest Dermatol 2006, 126:2257-2271. 10.1038/sj.jid.5700386, 16810302.
150. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009, 15:2988-2994. 10.1158/1078-0432.CCR-08-3172, 2682369, 19336521.
151. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003, 66:1537-1545. 10.1016/S0006-2952(03)00509-4, 14555232.
152. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004, 9:573-582. 10.1023/B:APPT.0000038036.31271.50, 15314285.
153. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002, 62:6231-6239.
154. Kahnberg P, Lucke AJ, Glenn MP, Boyle GM, Tyndall JD, Parsons PG, Fairlie DP. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J Med Chem 2006, 49:7611-7622. 10.1021/jm050214x, 17181145.
155. Holsken A, Eyupoglu IY, Lueders M, Trankle C, Dieckmann D, Buslei R, Hahnen E, Blumcke I, Siebzehnrubl FA. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 2006, 112:205-215. 10.1007/s00401-006-0082-8, 16773328.
156. Vozza A, Borriello A, Criniti V, Vozza G, Della RF. New established melanoma cell lines: genetic and biochemical characterization of cell division cycle. J Eur Acad Dermatol Venereol 2003, 17:37-41. 10.1046/j.1468-3083.2003.00644.x, 12602966.
157. Demary K, Wong L, Spanjaard RA. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 2001, 163:103-107. 10.1016/S0304-3835(00)00676-5, 11163113.
158. Kim SH, Ahn S, Han JW, Lee HW, Lee HY, Lee YW, Kim MR, Kim KW, Kim WB, Hong S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 2004, 315:964-970. 10.1016/j.bbrc.2004.01.149, 14985106.
159. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, Godard A, Blanchard F. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 2007, 26:881-892. 10.1038/sj.onc.1209844, 16909117.
160. Kobayashi Y, Ohtsuki M, Murakami T, Kobayashi T, Sutheesophon K, Kitayama H, Kano Y, Kusano E, Nakagawa H, Furukawa Y. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 2006, 25:512-524.
161. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, Garady C, Lai D, Yang X, Tron VA. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010, 176:2520-2529. 10.2353/ajpath.2010.091061, 20304954.